anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see Clinical Pharmacology (12.3)]. Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers (n≅70 patients) does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made.

In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.

Fluoxetine and Paroxetine

Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dose of Risperidone for Extended-Release Injectable Suspension. When initiation of fluoxetine or paroxetine is considered, patients may be placed on a lower dose of Risperidone for Extended-Release Injectable Suspension between 2 to 4 weeks before the planned start of fluoxetine or paroxetine therapy to adjust for the expected increase in plasma concentrations of risperidone. When fluoxetine or paroxetine is initiated in patients receiving the recommended dose of 25 mg Risperidone for Extended-Release Injectable Suspension, it is recommended to continue treatment with the 25 mg dose unless clinical judgment necessitates lowering the Risperidone for Extended-Release Injectable Suspension dose to 12.5 mg or necessitates interruption of Risperidone for Extended-Release Injectable Suspension treatment. When Risperidone for Extended-Release Injectable Suspension is initiated in patients already receiving fluoxetine or paroxetine, a starting dose of 12.5 mg can be considered. The efficacy of the 12.5 mg dose has not been investigated in clinical trials [see also Dosage and Administration (2.5)]. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.

Erythromycin

There were no significant interactions between oral risperidone and erythromycin.
PCT No. PCT/US93/07967 Sec. 371 Date Jul. 18, 1994 Sec. 102(e) Date Jul. 18, 1994 PCT Filed Aug. 24, 1993 PCT Pub. No. WO94/04574 PCT Pub. Date Mar. 3, 1994The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and IIIB as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC HB 10726 are specifically disclosed. Pharmaceutical compositions of the invention are projected to be useful in the passive immunization treatment of animals, especially humans, susceptible to or infected with HIV-1.
NEW MATERIAL:A bioactive protein specified by an amino acid sequence represented by the formula. USE:A preventive against plant virus infection, an antiviral agent and a protein synthesis inhibitor. PREPARATION:For example, seeds of Phytolacca americana L. are crushed using a mixer and subsequently washed with petroleum ether for removal of oily substances and deionized water is added to the resultant defatted powder. The obtained liquid is adjusted to pH 4.0 using hydrochloric acid, stirred for extraction of proteins and subjected to centrifugal separation for collection of an extracted solution. To the resultant extracted solution, ammonium nitrate is added until the solution is saturated in order to precipitate the proteins. The precipitated proteins are separated, dissolved in a small portion of water, dialyzed using a trishydrochloric acid buffer solution (pH8.5) and subjected to the anion-exchange column chromatography for collection of non-adsorbed fractions. The collected fractions are subjected to the cation-exchange column chromatography and then eluted by a linear concentration slope of 0-0.3M common salt, thus obtaining the objective bioactive protein of the formula.
The invention relates to aerated soap bars. Generally, it is difficult to get aerated soap bars with the right level of aeration, because high viscosity of the molten soap mass sometimes makes it difficult to aerate it to the desired extent. The size and movement of air bubbles also play important roles. Bars with larger air bubbles have lower mechanical strength. We have determined that use of acrylates or cellulose ethers in aerated soap bars lead to bars with acceptable rate of wear, mush and lower density. The soaps also have a higher and more uniform air incorporation and better air retention. Disclosed are aerated soap bars having density from 0.2 to 0.99 g/cm 3 , comprising: (i) 20 to 80 wt % soap; (ii) 2 to 40 wt % polyol; (iii) 5 to 50% water; and, (iv) 0.5 to 5 wt % electrolyte; wherein the bars comprise 0.1 to 5 wt % polymer selected from acrylates or cellulose ethers.
To develop and validate an enhanced CT-based radiomics nomogram for evaluating preoperative metastasis risk of epithelial ovarian cancer (EOC). One hundred and nine patients with histologically confirmed EOC were retrospectively enrolled. The volume of interest (VOI) was delineated in preoperative enhanced CT images, and 851 radiomics features were extracted. The radiomics features were selected by the least absolute shrinkage and selection operator (LASSO), and the rad-score was calculated using the formula of the radiomics label. A clinical model, radiomics model, and combined model were constructed using the logistic regression classification algorithm. Receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA) were used to evaluate the diagnostic performance of the models. Seventy-five patients (68.8%) were histologically confirmed to have metastasis. Eleven optimal radiomics features were retained by the LASSO algorithm to develop the radiomic model. The combined model for evaluating metastasis of EOC achieved area under the curve (AUC) values of 0.929 (95% CI 0.8593-0.9996) in the training cohort and 0.909 (95% CI 0.7921-1.0000) in the test cohort. To facilitate clinical use, a radiomic nomogram was built by combining the clinical characteristics with rad-score. The DCA indicated that the nomogram had the most significant net benefit when the threshold probability exceeded 15%, surpassing the benefits of both the treat-all and treat-none strategies. Compared with clinical model and radiomics model, the radiomics nomogram has the best diagnostic performance in evaluating EOC metastasis. The nomogram is a useful and convenient tool for clinical doctors to develop personalized treatment plans for EOC patients.
The invention relates to the technical field of biological pharmacy, and particularly relates to an antibacterial peptide, an antibacterial peptide hydrogel and a preparation method thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO. 1. Experiments show that the polypeptide has higher antibacterial activity and excellent biocompatibility. The antibacterial peptide hydrogel is prepared from antibacterial peptide, a photothermal reagent and a wound growth promoting factor. Tests show that the antibacterial peptide hydrogel has a good killing effect on bacteria on the surface of a biological membrane, particularly drug-resistant bacteria, can effectively crack and remove the bacterial biological membrane, promotes growth and proliferation of epidermal cells of a wound, collagen formation and angiogenesis regeneration, and realizes rapid healing of the wound infected by the bacterial biological membrane.
Histone chaperones are proteins that are involved in nucleosome assembly and disassembly and can therefore influence all DNA-dependent processes including transcription, DNA replication, and repair. ASF1 is a histone chaperone that is conserved throughout eukaryotes. In contrast to most other multicellular organisms, a deletion mutant of asf1 in the fungus Sordaria macrospora is viable; however, the mutant is sterile. In this study, we could show that the histone-binding ability of ASF1 is required for fertility in S. macrospora, whereas the function of ASF1 in maintenance of genome stability does not require histone binding. We also showed that the histone modifications H3K27me3 and H3K56ac are misregulated in the Δasf1 mutant. Furthermore, we identified a large duplication on chromosome 2 of the mutant strain that is genetically linked to the Δasf1 allele present on chromosome 6, suggesting that viability of the mutant might depend on the presence of the duplicated region.
The present invention discloses fusion protein having the function of promoting body growth, a coding gene and application thereof. The present invention has the purpose of providing fusion protein having the function of promoting body growth, a coding gene and application thereof to the preparation of therapeutic medicine for the growth hormone deficiency of children and adults. The fusion protein has the following amino acid residue sequences: 1) SEQ ID No. 1 in a sequence table and 2) protein which has the function of accretion promotion and is formed by means that the amino acid residue sequence of the SEQ ID No. 1 in the sequence table is replaced, deleted or added by one or ten amino acid residues. The fusion protein HSA-GH-RH provided by the present invention has the obvious function of accretion promotion and has the advantages of high expression amount, easy purification, short periodicity, large production scale and low cost. The present invention has great actual significance and wide application prospects in the fields of medicine and biologic pharmacy.
As a common complication of Crohn's disease (CD), the mechanism underlying CD intestinal fibrosis remains unclear. Studies have shown that epithelial-mesenchymal transition (EMT) is a key step in the development of intestinal fibrosis in CD. It is currently known that the long non-coding RNA (lncRNA) MSC-AS1 plays an important role in regulating the secretion of inflammatory mediators and EMT; however, its role in intestinal fibrosis remains unclear. MSC-AS1 was significantly upregulated in the CD intestinal tissue and intestinal tissue of mice treated with 2,4,6-trinitrobenzenesulfonic acid. Downregulation of its expression can inhibit EMT and alleviates intestinal fibrosis by regulating SNIP1. In addition, MSC-AS1 directly interacted with SENP1, blocking the deSUMOylation of SNIP1 and inhibiting its activity. Furthermore, we found that SENP1 enhanced the expression of SNIP1 and reduced intestinal fibrosis. In summary, MSC-AS1 regulates EMT through the SENP1/SNIP1 axis to promote fibrosis, and may be considered a potential molecular target for the treatment of CD and intestinal fibrosis.
The invention comprises compounds of the formula: <FORM:0854634/IV(b)/1> (wherein R is a phenyl radical which may be substituted by one or more alkyl groups or halogen atoms and R1 is a halogen atom) and their preparation by treating the corresponding 4-hydroxy compounds with halogenating agents such as phosphorus oxychloride. Examples describe the preparation of 1-phenyl- and 1-(p-chlorophenyl)-4-chloro-pyrazolo-(3 : 4-d)-pyrimidines. Specification 854,633 also is referred to.ALSO:Pharmaceutical compositions, stated to have fungicidal properties, comprise compounds of the formula:  <FORM:0854634/VI/1> (wherein R is a phenyl radical which may be substituted by one or more alkyl groups or halogen atoms and R 1 is a halogen atom) in admixture with pharmaceutical organic or inorganic carriers.  The compositions may be in the form of tablets dragees, salves, creams, solutions, suspensions or emulsions which may comprise suitable conventional excipients.  They may contain preserving, stabilizing, wetting or emulsifying agents or other therapeutically valuable substances. Specification 854,633 also is referred to.
Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab at the most appropriate dose and schedule determined in Part 1. Participants will continue to receive treatment as long as receiving clinical benefit or until disease progression.
Patients' expectations and beliefs regarding the potential benefits and harms of medical interventions may induce placebo and nocebo effects, and affect the response to pain therapies. In a randomized clinical trial, we examined the effect of placebo and nocebo expectations on pain relief and adverse events (AEs) in association with a topical treatment among 65 cancer survivors experiencing chronic musculoskeletal pain. Participants received either a 1% camphor-based topical pain patch or a placebo treatment for 14 days. We measured pain severity with the worst pain item of the Brief Pain Inventory (BPI) at baseline and 14 days and treatment expectations at baseline with validated expectation questionnaires. We found that high vs. low nocebo expectations decreased pain severity improvements by 2.5 points (95% confidence interval [CI] -3.8 to -1.2; p<0.001) on a 0-10 numeric rating scale of the BPI and pain response rate by 42.7% (95% CI 0.2-0.6; p<0.001) at day 14, irrespective of placebo expectation status or treatment arms. Patients with high vs. low nocebo expectations in the true arm reported 22.4% more unwanted AEs. High nocebo expectations were associated with increased AEs by 39.5% (odds ratio: 12.0, 95% CI 1.2, 145.5; p=0.029) and decreased pain response in the true arm vs. placebo. Our study demonstrated that nocebo expectations, rather than placebo expectations, elevate the risk of AEs and compromise the effect of topical pain interventions. The findings raise the possibility that nocebo expectations may worsen somatic symptoms through heightening central pain amplification and should be further investigated.
Patient response to sedative agents, and resultant respiratory status, is variable. Regardless of the intended level of sedation or route of administration, sedation is a continuum; a patient may move easily from light to deep sedation, with potential loss of protective reflexes. This is especially true in pediatric patients. Sedative doses should be individually titrated, taking into account patient age, clinical status and concomitant use of other CNS depressants. Continuous monitoring of respiratory and cardiac function is required (i.e., pulse oximetry).

### Adults and Pediatrics

Sedation guidelines recommend a careful presedation history to determine how a patient’s underlying medical conditions or concomitant medications might affect their response to sedation/analgesia as well as a physical examination including a focused examination of the airway for abnormalities. Further recommendations include appropriate presedation fasting.

Titration to effect with multiple small doses is essential for safe administration. It should be noted that adequate time to achieve peak central nervous system effect (3 to 5 minutes) for midazolam should be allowed between doses to minimize the potential for oversedation. Sufficient time must elapse between doses of concomitant sedative medications to allow the effect of each dose to be assessed before subsequent drug administration. This is an important consideration for all patients who receive intravenous midazolam.

Immediate availability of resuscitative drugs and age- and size-appropriate equipment and personnel trained in their use and skilled in airway management should be assured (see WARNINGS).

### Pediatrics

For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.

Intravenous access is not thought to be necessary for all pediatric patients sedated for a diagnostic or therapeutic procedure because in some cases the difficulty of gaining IV access would defeat the purpose of sedating the child; rather, emphasis should be placed upon having the intravenous equipment available and a practitioner skilled in establishing vascular access in pediatric patients immediately available.
Chromosomal instability (CIN), characterized by fluctuations in chromosome number or structure within cells, stands out as a hallmark of cancer, enabling tumors to thrive in hostile conditions. CIN serves as a driver of genetic diversity, giving rise to clonal heterogeneity (CH). Emerging evidence points to a potential correlation between CIN, CH, and the prognosis of breast cancer (BC) patients, especially in tumors exhibiting overexpression of the human epidermal growth factor receptor 2 (HER2+). However, our understanding of the role of CIN in other subtypes of BC is limited. Furthermore, it remains unclear whether CIN levels above a certain threshold in BC tumors could adversely affect tumor growth, or if lower to moderate levels of CIN might be associated with a more favorable prognosis for BC patients compared to elevated levels. Elucidating these relationships could significantly influence risk assessment and the formulation of future therapeutic approaches targeting CIN in BC. This study aimed to assess CIN and CH in tumor tissue samples obtained from Colombian patients diagnosed with luminal A, luminal B, HER2+, or triple-negative BC, and compare them with established clinicopathological parameters. The findings of this study indicate that BC patients exhibit intermediate CIN, high CH, and stable aneuploidy. All these characteristics were found to be related to clinicopathological features. Our results suggest that the identification of CIN, CH, and aneuploidy could improve cancer risk stratification, which could help to clarify the prediction of clinical outcomes and guide personalized therapeutic strategies for patients with different BC subtypes.
After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).
Refer to the manufacturer's manuals for specific instructions and precautions for performing the initial filling, refilling of the reservoir or replacement of the drug cartridge, and operation. The CADD-Micro Ambulatory Infusion Pump is filled for the first time with PRIALT solution at a concentration of 5 mcg/mL. This solution is prepared by diluting PRIALT with 0.9% Sodium Chloride, USP (preservative free). 

The recommended initial flow rate for the external microinfusion is 0.02 mL/hr to deliver the initial dose rate of 2.4 mcg/day (0.1 mcg/hr) of PRIALT. Changes in dose rate are made by adjusting the flow rate of the infusion system and/or the concentration of PRIALT solution. [see Warnings and Precautions (5.2)]
NEW MATERIAL:A compound expressed by the formula. USE:Healing promoter of injury, regenerating promoter after partially excising the liver and reagent for cancer test. PREPARATION:For example, a fresh duodenum of pig is treated in boiled water for 5min, homogenized with 0.1M acetic acid and extracted. Then, the extracted liquid is adsorbed into CM-cellulose, eluted with 0.1M hydrochloric acid and salted out to provide precipitates, which are then extracted with isopropyl alcohol and then with methanol. The extracted liquid is concentrated to dryness and dissolved in 0.1M citric acid.phosphoric acid buffer solution (pH6.5) and the resulting solution is poured into CM-cellulose to provide an unadsorbed fraction. Water is then added to the fraction and purification is carried out by subjecting the resultant fraction to iron-exhange column chromatography, reversed phase chromatography, etc., to give the aimed novel peptide.
PURPOSE: To obtain a cosmetic characterized by containing Fuscoporia obliqua Fr. extract, cultured mycelia extract or culture fluid. CONSTITUTION: This cosmetic has anti-inflammatory effect and is characterized by containing Fuscoporia obliqua Fr. extract, cultured mycelia extract or culture fluid. The Fuscoporia obliqua Fr. is a kind of mushroom belonging to Mucronoporaceae, consisting of basidiocarp and sclerotium, and a commercial product as well as native one thereof may be used. The culture of this mushroom can be conducted easily in a medium for conventional microbes or mushroom, the cultured mycelia and culture fluid therefrom being also be used. This cosmetic can take a preparation form such as skin care product, makeup cosmetic, bathing agent, or hair cosmetic.
BACKGROUND: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and is linked to significant symptoms and an elevated risk of heart failure, thromboembolism and disabling stroke. Not only do patients suffer from AF and the concomitant complications, but it is a great economic burden for healthcare systems all over the world. Despite remarkable progress in the field of AF, the basic mechanisms of AF development remain unresolved. Data suggests that the (cardiac) autonomous nervous system (ANS) plays a significant role in AF. Recent studies have shown that stimulating the ANS could have a beneficial effect on paroxysmal and postoperative AF. Consequently, this therapy could provide another viable target for treating persistent AF, as well.
METHODS: The VAST-AF trial is a prospective, double-blinded, randomized, and sham-controlled clinical trial. One hundred and twenty patients diagnosed with persistent AF and cardioversion in sinus rhythm (SR) will be randomly assigned to either transcutaneous vagal nerve stimulation (tVNS) or sham treatment in a 1:1 ratio. The primary objective of this study is to examine whether a daily tVNS reduces the recurrence rate of AF. Secondary endpoints include quality of life, time to first AF recurrence and ECG parameters of the ANS. Follow-up is scheduled at 30 days, 3 and 6 months. After 3 months, stimulation is withdrawn, and patients evaluated regarding a still detectable effect of tVNS.
CONCLUSION: The VAST-AF trial represents the first randomized and sham-controlled study to investigate the potential benefits of transcutaneous vagal nerve stimulation on the recurrence of atrial fibrillation. Patients with persistent atrial fibrillation and successful electrical cardioversion will be assessed. A decrease in the rate of recurrence and consecutive hospitalizations could decidedly enhance the quality of life of patients and decrease healthcare expenses. Nevertheless, it does not compete with treatments such as catheter ablation, but rather serves as an additional tool in the armamentarium of the electrophysiologist.